Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). (Q40589436)

21 September 2017

title

Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). (English)

1 reference

21 September 2017

Noriyuki Sato

1 reference

21 September 2017

Takayuki Kanaseki

1 reference

21 September 2017

Takashi Tokino

1 reference

21 September 2017

Hideyuki Ikeda

1 reference

21 September 2017

Yukio Takamura

1 reference

21 September 2017

Minoru Toyota

series ordinal

1 reference

21 September 2017

Kohzoh Imai

series ordinal

1 reference

21 September 2017

Kiyohiro Houkin

series ordinal

1 reference

21 September 2017

publication date

1 March 2004

1 reference

21 September 2017

1 reference

21 September 2017

1 reference

21 September 2017

1 reference

21 September 2017

page(s)

392-405

1 reference

Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

Isoforms of the class II transactivator protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Is poor prognosis really related to HLA-DR expression by malignant melanoma cells?

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Invariant chain structure and MHC class II function

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

The makings of a tumor rejection antigen

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Histone acetylation in chromatin structure and transcription

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Expression of MHC class II antigens in human lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Signaling pathways regulating gliomagenesis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA)

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Progress in human tumour immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Brain tumor survival: results from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Genetic control of MHC class II expression

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Human tumor antigens for cancer vaccine development

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

DNA content and MHC class II antigen expression in malignant melanoma: clinical course

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.10343

7 January 2021

Identifiers

DOI

10.1002/GLIA.10343

1 reference

21 September 2017

1 reference